Pathogenicity was reportedly restored to an avirulent molecular clone of equine infectious anemia virus (EIAV) by substitution of 3Ј sequences from the pathogenic variant strain (EIAV PV ). However, the incidence of disease in horses/ponies was found to be significantly lower (P ϭ 0.016) with the chimeric clone (EIAV UK ) than with EIAV PV . This was attributable to 3Ј rather than 5Ј regions of the proviral genome, where EIAV UK differs from the consensus EIAV PV sequence by having a 68-bp duplication in the 3Ј LTR and arginine (R 103 ) rather than tryptophan (W 103 ) at position 103 in the second exon of rev. In EIAV UK recipients the duplication was rapidly eliminated and R 103 replaced by W 103 in the viral population. Furthermore, removal of the 3Ј variant sequences from EIAV UK (EIAV UK3 ) resulted in an equivalent (P ϭ 0.013) disease potential in Equus caballus to EIAV PV . The 68-bp duplication and/or R 103 may limit peak viral RNA accumulation during acute infection.
Introduction
Infectious molecular clones of equine infectious anemia virus (EIAV) are potentially extremely valuable for identifying the genetic elements responsible for pathogenicity in this lentivirus. It was previously reported that virulence in Equus caballus was conferred on a nonpathogenic infectious molecular clone of EIAV by substitution of 3Ј sequences derived from the pathogenic variant strain (EIAV PV ). The resultant chimeric molecular clone was designated EIAV UK (Cook et al., 1998) and was initially observed to produce signs of acute equine infectious anemia (EIA) in three of four horse/pony recipients by 12 days postinfection (dpi). These clinical signs consisted of a transient high fever (Ն39°C) and thrombocytopenia, although this lacked the severity required to interfere with bloodclotting ability (Cook et al., 1998) .
A fundamental property of the acute disease induced by EIAV PV in E. caballus is that it is non-life-threatening and invariably resolved within 1 to 3 days. If severe clinical signs occur as a result of infection with this virus, they are confined to the subsequent chronic stage of the disease Wang et al., 1994; Hammond et al., 1997) . This contrasts with EIAV WYOMING (EIAV WY ) infections of horses or ponies. Although this viral strain is the progenitor of EIAV PV (Malmquist et al., 1973; Orrego et al., 1982; Rwambo et al., 1990 ) it often produces a very severe, fatal form of acute EIA (Kemeny et al., 1971; Issel, unpub-lished data) . Therefore, EIAV PV and EIAV WY occupy different areas in the broad spectrum of acute disease potential observed with this lentivirus Sellon et al., 1994; Cook et al., 1996) . As a result of the initial observations, EIAV UK was interpreted as being directly equivalent to EIAV PV (Cook et al., 1998) and was assumed to contain the genetic determinants responsible for causing episodes of moderate acute EIA. Furthermore, by comparison (Cook et al., 1998) with other viral strains, including a consensus sequence for 3Ј regions of the EIAV PV genome (Lichtenstein et al., 1996; Leroux et al., 1997) , these determinants were mapped to transcription factor binding motifs within the LTR and/or to specific env gene sequences, including some in open reading frame (ORF) S3 (encoding the second exon of rev). However, this conclusion was challenged by a subsequent study in which 3 EIAV UK pony recipients showed no overt clinical signs during a 180-day observation period (Feng Li et al., 2000) . Consequently, EIAV UK was calculated to have a disease induction rate of 43% (3 of 7 recipients) compared to 87% seen in a survey (Cook et al., 1998) of 23 (20 of 23 recipients) EIAV PVinfected horses and ponies. Application of the Pearson 2 test to these results produced strong evidence for a significant (P ϭ 0.016) difference between EIAV PV and EIAV UK in the ability to rapidly induce acute EIA in populations of E. caballus.
It was hypothesized that this difference in pathogenicity could be the result of genetic variation between EIA-V UK and the predominant members of the EIAV PV population, as represented by the consensus nucleotide sequence. Previous analysis had demonstrated that EIA-V UK differed at two locations from the consensus sequence for 3Ј regions of the EIAV PV genome (Lichtenstein et al., 1996; Leroux et al., 1997) . These consisted of an unusual 68-bp duplication in the U3 region of the 3Ј LTR and the presence of arginine (R 103 ) rather than tryptophan (W 103 ) at amino acid position 103 in ORF S3 (Cook et al., 1998) . In addition to these previously identified differences it was noted that only 40% of the EIAV UK genome was derived from EIAV PV , while the remaining 60% was from the original avirulent molecular clone (Cook et al., 1998) . As gag and much of the EIAV PV pol gene have not been sequenced it was considered feasible that biologically significant variation might exist in these regions of the viral genome compared with EIAV UK .
In this report evidence for consistent nonsynonymous nucleotide differences in gag/pol between EIAV UK and EIAV PV is presented, although this did not correlate with pathogenicity. Instead the variation in disease potential was found to map to 3Ј regions of the viral genome. In EIAV UK -infected animals the 68-bp duplication in the LTR was rapidly deleted from the viral population and R 103 was replaced by W 103 . Furthermore, viruses from a variant of EIAV UK (EIAV UK3 ) that lacked the 68-bp duplication and possessed W 103 induced transient, moderate acute febrile episodes in seven of eight recipients.
Results

Plasma-associated viral RNA levels following infection with EIAV UK
Highly pathogenic strains of EIAV are expected to induce clinical signs within 42 days of infection in at least 80 to 90% of horse/pony recipients. However, as previously reported (Cook et al., 1998; Feng Li et al., 2000) , the appearance of clinical signs within this time frame was only observed in three of seven EIAV UK -infected animals. In Figs. 2A and B the plasma-associated viral RNA load in all EIAV UK recipients during the period of acute viral replication is shown in the context of temperature profile and platelet concentration. As expected the febrile episodes in horses 614, 700, and 764 were associated with high viral RNA burdens, although the amounts varied by almost 10-fold from 1.44 ϫ 10 7 copies/ml in 700 to 1.05 to 10 8 copies/ml in 764 ( Fig. 2A) . Furthermore, there was not an absolute correlation between the level of viral RNA and pyrexia. For example, the body temperatures of horses 94-14 and 94-20 remained well within the normal range for E. caballus considering that both animals had viral RNA loads very similar to those detected in horse 700 during a period of pronounced fever (39.4°C, Figs. 2A and B) . In addition, the body temperature of horse 700 did not remain elevated despite the fact that viral RNA levels at 15 and 21 dpi either exceeded or were similar to those measured during the pyrexia episode at 12 dpi ( Fig. 2A) . The viral RNA load data also suggested that some animals could control initial EIAV UK replication more effectively than others. This was particularly evident between 94-17, which remained asymptomatic, and 764 ( Figs. 2A and B) . Interestingly, 764 not only had the highest viral RNA burden associated with acute disease of all EIAV UK -infected animals but was the only recipient of this virus to experience additional febrile episodes that eventually became severe enough to require euthanization (Cook et al., 1998) . Fig. 2 . Clinical profiles of horses/ponies monitored during the early stages of EIAV UK infection for those animals that became febrile (A) and those that remained afebrile (B). The rectal temperature (solid line) and platelet level (dotted line) expressed as platelets per microliter of whole blood are shown in conjunction with the plasma-associated viral RNA burden (log 10 /ml, hatched bars) as determined by a multiplex real-time RT-PCR assay.
Analysis of EIAV PV gag-pol sequences
Most of the 5Ј region in the EIAV PV genome has not been characterized. Therefore, DNA from EIAV PV -infected cells was amplified by PCR using the 1-4861 oligonucleotide primer pair (Fig. 1 , Table 1 ) and molecularly cloned into the pLG330/30 plasmid vector and four of the resultant clones (EIAV PV4.9 a-d) were subjected to nucleotide sequence analysis. All of the EIAV PV4.9 clones tested were identical to EIAV UK in the gag gene regions encoding the matrix, core, and nucleocapsid proteins (Fig. 3A) . However, they differed from EIAV UK in having the codon for histidine instead of an asparagine residue at amino acid position 45 in the carboxyl terminal domain of the P9 protein (Fig.  3A) . In addition, one EIAV PV4.9 clone (d) encoded a proline instead of a leucine residue at amino acid position 44 in P9 (Fig. 3A) .
Analysis of pol gene sequences to the NcoI restriction endonuclease at nucleotide position 4873 demonstrated that the majority of differences between EIAV PV4.9 and EIAV UK were located in the region encoding reverse transcriptase (RT). Each EIAV PV4.9 clone contained codons for valine instead of methionine at position 189, arginine instead of leucine at position 196, and valine instead of isoleucine at position 271 (Fig. 3B) . Furthermore, three clones (a, c, and d) differed from the RT of EIAV UK at the codon for amino acid position 425 (lysine instead of arginine) and two of the clones (b and c) varied at position 293 (isoleucine instead of valine). Some minor variation in RT between EIAV UK and individual EIAV PV4.9 clones was also observed (Fig. 3B) . Nonsynonymous nucleotide sequence differences with EIAV UK in regions encoding protease, dUTPase (DU), and the amino terminal region of integrase were not conserved between individual EIAV P4.9 clones (Fig. 3B) . Complete homology between EIAV UK and consensus EIAV PV sequences has been previously demonstrated for the remaining section of the pol gene encoding the carboxyl terminal domain of integrase (Lichtenstein et al., 1996; Leroux et al., 1997; Cook et al., 1998) .
Substitution of EIAV PV4.9 sequences in EIAV UK and infection of ponies with the resultant chimeric viruses
The nucleotide sequence analysis described above suggested the existence of consistent potential amino acid differences between EIAV UK and the majority of the EIAV PV population in gag p9 and RT. As three of the EIAV PV4.9 molecular clones (b, c, and d) had minor inconsistent variations in regions of the pol gene outside RT, EIAV PV4.9A was selected for the subsequent work culminating in animal trials. A 4.23-kbp fragment derived by AspI-NcoI restriction endonuclease digestion of EIAV PV4.9A ( Fig. 1) was substituted for equivalent sequences in EIAV UK and the resultant chimeric molecular clone, designated EIAV UK2 , transfected into fetal equine kidney (FEK) cells. Following titration in FEK cells, viruses derived from EIAV UK2 were used to inoculate two ponies (873 and 930) at a dose of 4 ϫ 10 6 TCID 50 . These animals became infected, as evidenced by seroconversion to EIAV antigens in the CELISA, but neither showed signs of a febrile response during a 42-day observation period (Fig. 4) . Although only two animals were infected, this experiment suggests that either EIAV PV4.9A was not the optimum donor for gag/pol sequences (possibly because of the additional variation in RT compared to the other EIAV PV4.9 clones examined, Fig. 3B ) or that the pathogenic potential of EIAV UK was reduced by differences from EIAV PV in 3Ј rather than 5Ј regions of the proviral genome.
Stability of the 68-bp duplication in the EIAV UK LTR in vivo
If the 68-bp duplication in the 3Ј LTR of EIAV UK and/or the possession of R 103 instead of W 103 were detrimental to viral replication it is predicted, they would be exposed to strong selective pressure in vivo.
To test the stability of the 68-bp duplication in vivo viral RNA samples were isolated from the plasma of three EIAV UK -infected horses/ponies that developed acute EIA within 42 dpi (614, 700, and 764) and three (613, 94-14, and 94-20) that did not (Cook et al., 1998; Feng Li et al., 2000) . A region encompassing this duplication in these samples was amplified by RT-PCR using the oligonucleotide primer pair 7812/8179 (Table 1 ). This primer pair was designed to produce a 398-bp fragment with RNA containing the repeated element and a 330-bp fragment with samples having a 3Ј U3 region of the standard size. DNA products having these predicted sizes were generated using the 7812/8179 primer pair in RT-PCR amplification of RNA isolated from EIAV UK and EIAV PV virions, respectively (Fig. 5) . The earliest time point at which products were reliably detected in EIAV UK recipients following RT-PCR with 7812/8179 was 7 dpi. In all cases at this time, a fragment was produced that comigrated with an equivalent product generated from the EIAV UK virus stock (Fig. 5) . Although this was exactly as predicted it was something of a surprise to find a second amplified product comigrating with the fragment produced from 7812/8179 RT-PCR of EIAV PV virions (Fig. 5) . Furthermore, as the infection progressed the relative intensity of the lower molecular weight fragment appeared to increase, until by 21 dpi it was the only detectable product (Fig. 5) . The relative amounts of the two RT-PCR products was estimated in the six EIAV UK recipients using an IS-1000 Digital Imaging System (Alpha Innotech Corp., San Leardo, CA), with the effects of DNA fragment size on ethidium bromide binding corrected by multiplying the fluorescent intensity of the smaller product by a factor of 398/390. This demonstrated that at 7 dpi the smaller fragment comprised between 43 and 64% of the total 7812/8179 RT-PCR product and that by 12 dpi this had increased to between 72 and 89%. These results suggested that viruses derived from EIAV UK were subject to strong selective pressure in vivo resulting in replacement of the original infection population by a variant containing at least one deletion in the 3Ј terminal region of the genome. To locate potential deletions the 7812/8179 RT-PCR fragments generated using samples harvested at 8 and 12 dpi from four EIAV UK recipients were molecularly cloned and subjected to nucleotide sequencing. For this analysis, 5 upper and 5 lower fragment molecular clones from each animal at both time points were examined. Therefore, in total representatives from 40 higher molecular weight and 40 lower molecular weight fragments were sequenced.
In each case the larger RT-PCR fragment was found to contain an intact 68-bp duplication, whereas the LTR sequences in the smaller fragment were identical to the consensus for EIAV PV (Lichtenstein et al., 1996; Leroux et al., 1997) . Therefore in horses/ponies EIAV UK is replaced by a viral population from which the 68-bp duplication has been deleted in a precise and consistent manner.
Identity of the amino acid residue at position 103 in ORF S3 in EIAV UK -infected animals
Following observations showing that the 68-bp duplication was unstable, studies were initiated to determine if the codon for the arginine residue at amino acid position 103 in ORF S3 of EIAV UK was maintained or replaced in vivo. Viral RNA from the cell culture-derived stock of EIAV UK or plasma from animals infected (613, 614, 700, 764, 94-14, and 94-20) with this virus was amplified by RT-PCR using the 7034/8179 oligonucleotide primer pair (Table 1) . The resultant 1107-bp product was molecularly cloned into the pT7 Blue 3 plasmid vector and subjected to nucleotide sequence analysis using previously described oligonucleotide primers (Leroux et al., 1997) . For each RNA sample a minimum for four individual molecular clones were analyzed to determine the potential identity of the residue at amino acid position 103 in ORF S3. In each clone sequenced from the cell culture-derived viral stocks of EIAV UK this residue was deduced to be arginine, just as in the original molecular clone ( Table 2 ). The next samples analyzed were from plasma harvested during febrile episodes. In horses 700 and 764, which had fever at 12 dpi (Cook et al. 1998) , all clones examined possessed the original arginine at position 103. However, in pony 614, which also had fever at 12 dpi (Cook et al. 1998 ), 22% of the clones possessed tryptophan at this position (Table 2) . Furthermore, in samples from horse 764 taken during a subsequent, very severe febrile episode at 55 dpi (Cook et al. 1998 ) all of the clones tested had arginine replaced by tryptophan ( Table 2 ). The final phase of this analysis was conducted on animals that did not experience disease during the period of observation. In clones from 94-14 and 94-20 at 31, 46, or 82 dpi, a tryptophan residue was invariably present at position 103 in ORF S3.
Infection of horses/ponies with viruses derived from EIAV UK3
The rapid, selective changes in the EIAV UK population observed in infected horses or ponies suggested that viruses derived directly from this molecular clone were not optimal in terms of replicative efficiency in vivo. Therefore, EIAV UK was modified by removal of the 68-bp duplication and by replacement of arginine at position 103 in ORF S3 by tryptophan. This was accomplished by substitution of a BstXI/EcoRI fragment ( Fig. 1) from an EIAV PV3.3 molecular clone (Cook et al. 1998 ) that lacked these atypical features and was, within this particular region, homologous to the consensus sequence for EIAV PV (Lichtenstein et al. 1996; Leroux et al. 1997) . The modified molecular clone was designated EIAV UK3 and viruses derived from it were used to infect 10 horses/ponies at a dose of 4 ϫ 10 6 TCID 50 . However, 2 of these animals were observed to have preexisting thrombocytopenia and although both experienced febrile episodes they were excluded from further analysis. In all of the remaining animals, infection was associated with a decline in platelet numbers that ranged from 16 to 68%, with a geometric mean of 37% (Figs. 4A and B) . More importantly, with the exception of horse 9 all EIAV UK3 recipients had at least one febrile episode (Ն39°C) that occurred between 9 and 13 dpi (Fig. 6) .
Serological responses to infection with EIAV UK3 were examined using a commercially available ELISA (Vira-CHEK/EIA). In this test horses 662, 839, 6, and 10 were seropositive to the p26 core antigen by 14 dpi, while 985, 986, 1, and 9 seroconverted by 21 dpi.
The amount of infectious virus present in plasma collected at the time of maximum febrile response was determined by titration on FEK cells. In each case a rectal temperature of Ն 39°C was associated with a plasma viremia level of at least 10 5 TCID 50 /ml. A more detailed picture of the early pattern of EIAV UK3 replication was provided by the analysis of plasma-associated viral RNA levels (Fig. 6) . In general the profile of viral RNA accumulation was similar to that in EIAV UK recipients, with maximal burdens occurring between 10 and 14 dpi. However, the peak levels detected following infection with EIAV UK3 appeared to be somewhat higher than those with EIAV UK (Fig. 6 ).
Statistical analysis of EIAV UK and EIAV UK3 infection experiments in vivo
Analysis of the clinical data from these experiments by the Pearson 2 test provided at least some evidence for the hypothesis that the incidence of disease in the EIAV UK3 -infected group was significantly (P ϭ 0.067) higher than RNA isolated from plasma was amplified by RT-PCR using the oligonucleotide primer pair EIAV 7034/8179 , molecularly cloned into the pT7 Blue 3 vector, and the amino acid at position 103 in ORFNS3 deduced from the nucleotide sequence. A minimum of four individual molecular clones were sequenced from each time point designated as days postinfection (dpi). The single letter code is used to denote the amino acid residue present.
a Cell culture-derived stock from EIAV UK . b Sample collected during a febrile episode. c EIAV UK recipients that remained afebrile.
that in animals receiving EIAV UK . However, there was more rigorous support based on an analysis of the real-time RT-PCR data by the T test for the occurrence of significant differences (P ϭ 0.02) between EIAV UK -and EIAV UK3 -infected groups in peak plasma-associated viral RNA levels. It was calculated that on average the peak viral RNA load in the EIAV UK3 -infected subjects was 1.72 ϫ 10 8 copies/ml, whereas on average that in the EIAV UK recipients was 2.85 Fig. 6 . Clinical profiles of horses/ponies monitored during the early stages of EIAV UK3 infection. The rectal temperature (solid line) and platelet level (dotted line) expressed as platelets per microliter of whole blood are shown in conjunction with the plasma-associated viral RNA burden (log 10 /ml, hatched bars) as determined by a multiplex real-time RT-PCR assay. ϫ 10 7 copies/ml. In addition a linear regression model was developed to evaluate dpi and the identity of the molecular clone as factors involved in predicting viral RNA copy number. The model, in which a log transformation was used on both dpi and the number of copies, was a good fit (P ϭ 0.0001) and indicated that both dpi and the type of molecular clone (EIAV UK or EIAV UK3 ) were significant in predicting the number of plasma-associated viral RNA molecules (P ϭ 0.0001 and P ϭ 0.0067, respectively).
Comparison of EIAV UK and EIAV UK3 in equine monocytederived macrophage (MDM) and FEK cell cultures
To investigate if EIAV UK3 replicated to higher titers than EIAV UK in vitro, viruses from each of the two molecular clones were used to infect eight equine MDM cultures at a m.o.i. of 0.1 TCID 50 . The cytopathic effect progressed at equivalent rates and with both viruses and was Ͼ95% complete by 6 dpi. At this time point amounts of viral RNA present in the cell culture fluids were determined because previous studies (Raabe et al., 1998; Cook, unpublished data) using similar levels of infectivity have shown that this corresponds with the maximum detectable yield of progeny virions. Application of the T test to the final results demonstrated there were no significant differences (P ϭ 0.44) between EIAV UK (mean, 7.55 ϫ 10 8 viral RNA copies/ml, SD, 2.57) and EIAV UK3 (mean, 8.68 ϫ 10 8 viral RNA copies/ml, SD, 3.10). Similarly, analysis of the viral RNA copy from a minimum of four independently transfected FEK cell cultures for each molecular clone produced no evidence for statistically significant differences (P ϭ 0.618) in peak levels of accumulation between these viruses (EIAV UK mean, 4.75 ϫ 10 10 viral RNA copies/ml, SD, 2.90; EIAV UK3 mean, 3.64 ϫ 10 10 viral RNA copies/ml, SD, 3.36), confirming earlier studies in which viral yields from EIAV UK -and EIAV UK3 -infected macrophage and FEK cultures were determined by titration in FEK cells.
Comparison of the EIAV UK and EIAV UK3 LTRs in a reporter gene assay
Potential transcriptional effects of the 68-bp duplication were investigated by comparing the activities of the EIAV UK and EIAV UK3 LTRs in a chloramphenicol acetyltransferase (CAT) reporter gene assay. An intact copy of the 3Ј LTR from each infectious molecular clone was amplified by PCR and ligated into the pCAT-basic vector to generate pUKLTR-CAT and pUK3LTR-CAT. Plasmid DNA from two separate preparations (a 1 ,b 1 ,a 2 ,b 2 - Table 3A ) of each LTR-CAT clone were transfected in triplicate into equine dermal (ED) cells in conjunction with the EIAV tat protein expression vector pRS-ETAT-M (Dorn et al., 1990) . As a control a single plasmid preparation was made in which pUKLTR-CAT (a 1 ) and pUK3LTR-CAT (a 2 ) were cotransfected in triplicate in ED cells with an expression vector (pCI) that lacked any form of insert. In the presence of the tat expression vector there were no significant differences (P ϭ 0.403) between the LTR constructs in amounts of CAT produced (Table 3A) . As expected, only residual amounts (0.3%) of CAT were detectable in pUK3LTR-CAT-transfected cells when tat was absent. However, the 68-bp duplication in the EIAV UK LTR resulted in increased basal transcriptional activity that was 20% of that observed in the presence of tat. To ensure that this result was not associated with a particular plasmid DNA preparation, three independent plasmid preparations of pUKLTR-CAT (b 1 ,c 1 ,d 1 ) and pUK3LTR-CAT (b 2 ,c 2 ,d 2 ) were each transfected in triplicate into ED cells. Analysis of CAT production in these cell cultures confirmed that basal, tat-independent transcription from the LTR of EIAV UK was significantly (P Ͻ 0.0001) higher than that from EIAV UK3 (Table 3B) .
Discussion
A comparison between the genomes of EIAV UK and EIAV PV revealed a number of sequences that could be responsible for the significant differences (P ϭ 0.016) be- tween those viruses in the ability to rapidly induce acute EIA in populations of E. caballus. Evidence for consistent nonsynonymous nucleotide differences between EIAV UK and EIAV PV in the gag p9 protein and in the 51-kDa subunit (DeVico et al., 1991; Wohrl et al., 1994) of reverse transcriptase was provided by nucleotide sequencing of four EIAV PV4.9 molecular clones. As gag p9 is essential for the release of nascent viral particles from the host cell plasma membrane (Puffer et al., 1997; Chen et al., 2001; Li et al., 2002) and as reverse transcriptase produces complementary viral DNA from genomic RNA, variation in either of these key structural components could have a significant impact on viral replication. However, the accumulated evidence argues against potential variation in gag/pol being the main contributing factor to the difference in pathogenicity between EIAV UK and EIAV PV . Signs of acute disease were not observed in either of the two ponies infected with a variant of EIAV UK (EIAV UK2 ) containing gag/pol sequences from EIAV 4.9A . In addition, EIAV UK3 , whose gag/ pol sequences were unaltered from EIAV UK , produced a similar (P ϭ 0.03) incidence of acute EIA to EIAV PV in populations of E. caballus and finally, early clinical signs were induced in two of two ponies infected with a variant (EIAV UK4 ) of EIAV UK2 (produced by substitution of the 3Ј 3.3-kbp NcoI/EcoRI fragment shown in Fig. 1 from EIAV UK3 ) containing 3Ј sequences derived from EIAV UK3 (R.F. Cook, unpublished data). It therefore appears that variation between EIAV UK and EIAV PV in gag/pol is restricted to highly conservative amino acid substitutions and/or is located within domains not connected with determinants of virulence. Support for the notion of conservative substitutions is seen in reverse transcriptase where a nonpolar methionine at position 189, a positively charged lysine at position 196, and a nonpolar valine at position 251 in EIAV UK are replaced in all EIAV PV4.9 clones by a nonpolar valine, positively charged arginine, and nonpolar isoleucine, respectively. Similarly, the positively charged arginine residue at position 405 in EIAV UK is represented by a positively charged lysine in three of the four EIAV PV4.9 clones.
A potentially less conservative substitution is seen at amino acid position 45 in gag p9, where a polar asparagine residue in EIAV UK is replaced by a positively charged histidine in all four EIAV PV4.9 clones. However, as this substitution is located in the carboxyl terminus of the 51-amino-acid protein it is significantly downstream from the tyrosine (Y), proline (P), aspartic acid (D), leucine (L) late domain (amino acid positions 23 to 26) that is indispensable for virus particle budding (Puffer et al., 1997; Chen et al., 2001; Li et al., 2002) . Furthermore, the carboxyl terminus of p9, including amino acid position 45, can be deleted without complete abrogation of function (Chen et al., 2001 ), suggesting that this domain has an ancillary or modulatory role that may not be compromised by the substitution of certain amino acids.
As a result of the failure to implicate differences in the gag/pol genes, it could be inferred that pathogenicity is attenuated by the 68-bp duplication in the 3Ј LTR and/or the presence of arginine (R 103 ) instead of tryptophan (W 103 ) at position 103 in ORF S3, as these are the only other variant sequences identified between EIAV PV and EIAV UK (Cook et al., 1998) . The fact that in all the EIAV UK recipients examined this duplication was deleted and R 103 replaced by W 103 shows that there is a strong selective mechanism for generating viral populations resembling the EIAV PV consensus sequence at these locations. This consistent evolutionary pressure therefore conclusively demonstrates that the 68-bp duplication and R 103 are both less than optimal for the EIAV life cycle in vivo. Furthermore, removal of these variant sequences from EIAV UK (EIAV UK3 ) increased the incidence of acute disease in populations of E. caballus.
To account for these observations it is proposed that EIAV burden must reach a critical or threshold level to trigger sufficient release of pro-inflammatory cytokines such as tumor necrosis factor-␣, interleukin-6, and transforming growth factor-␤ that have been implicated in the pyrexia and thrombocytopenia associated with acute EIA (Costa et al., 1997; Tornquist et al., 1997; Sellon et al., 1998) . Although this replication proceeds unopposed in foals with severe combined immunodeficiency (Perryman et al., 1988; Mealey et al., 2001) , resulting in a fatal acute disease, in normal horses/ponies it is counteracted by the development of powerful adaptive immune responses Hammond et al., 1997) . Therefore, the clinical outcome following infection with EIAV PV -like viruses can be visualized as a race between viral replication leading to high viral burdens and the establishment of initial immunological control. In this model the replicative potential of EIAV in vivo is the primary determinant of pathogenicity.
It is estimated, based on real-time RT-PCR data collected to date (this study and R.F. Cook, unpublished) , that the threshold level for the induction of acute disease in a majority of horses/ponies is correlated with a plasma-associated viral RNA load of 5 ϫ 10 7 to 1 ϫ 10 8 copies/ml. Comparison of the calculated average peak plasma viral RNA level between EIAV UK (2.85 ϫ 10 7 copies/ml) and EIAV UK3 (1.72 ϫ 10 8 copies/ml) infections indicates that the presence of the 68-bp duplication and/or R 103 results in an average sixfold decrease in the maximal accumulation of viral genetic material. Therefore the 68-bp duplication and/or R 103 are predicted to slow the rate of EIAV accumulation such that in most cases, the threshold level is not reached before the rapidly developing immune response becomes sufficiently effective to curtail viral replication. Furthermore, once established the immune response apparently continues to restrict EIAV UK replication even though the viral population undergoes apparent increases in biological fitness by deleting the 68-bp duplication and replacing R 103 with W 103 . Under these circumstances EIAV UK could only induce disease if the increases in biological fitness were accompanied by antigenic changes to permit evasion of the immune response. Those EIAV UK -infected animals that succumbed to acute disease appeared to represent a minority of the horse population in which viral replication was either less efficiently contained (suggested in the case of 764) or febrile episodes were triggered at a lower viral burden threshold (a possible explanation for clinical signs in 614 and 700).
The mechanisms involved in limiting peak viral RNA accumulation by the 68-bp duplication and/or R 103 remain to be determined. Although it is located upstream from all previously identified, cis-acting transcriptional control elements Derse et al., 1987; Maury, 1994 Maury, , 1998 , analysis using the MatInspector 2.2 algorithm (Quandt et al., 1995) suggested that the duplication could introduce new transcription factor binding motifs with an 85.5% core sequence homology to Tata box elements, the binding sites for interferon regulatory factors 1 and 2, the mouse homeobox gene S8, the C-myb proto-oncogene, and the barbiturate inducible element. Therefore, the presence of the duplication might result in the recruitment of additional nuclear transcription factors that could interfere with normal viral RNA synthesis. The experimental evidence showing no significant differences in progeny virus production from MDM or FEK cells and equivalent tat-associated CAT reporter gene transcription from the EIAV UK and EIAV UK3 LTRs demonstrates that if such interference occurs it can only be of a very small magnitude. However, this does not exclude the possibility of direct effects on viral transcription because dramatic shifts in viral populations can be caused by just small (1-2%) differences in fitness between variants (Duarte et al., 1994) . Such differences are unlikely to be detectable by simple, noncompetitive cell infectivity or CAT reporter gene assays because of their inherent variability and relative insensitivity. However, the CAT assay data suggests some intriguing alternative mechanisms. In the absence of tat the promoter activity of the EIAV LTR is normally reduced by at least 100-fold (Dorn et al., 1990; Noiman et al., 1990; Carroll et al., 1991; Rosin-Arbesfeld et al., 1998) . Although this reduction was confirmed with the EIAV UK3 LTR only a fivefold decrease was observed in tat-independent promoter activity from the 3Ј LTR of EIAV UK . Therefore, the 68-bp duplication appears to constitute at least in part a relatively active transcriptional unit that is not under the normal rigorous control of tat. If this relaxation in transcriptional control altered the pattern of EIAV protein production, particularly in monocytes, where viral expression is quiescent until cell differentiation is complete (Maury, 1994) , it could increase the exposure to protective immune responses.
In addition to the 68-bp duplication, the presence of R 103 in ORF S3 could also have a significant impact on the accumulation of peak viral RNA levels in vivo. The EIAV rev protein, of which the second exon is encoded by ORF S3, plays a viral role in EIAV replication by facilitating the nuclear export of unspliced genomic and singly spliced viral RNAs (Saman et al., 1990 ; Rosin-Arbesfeld et al., 1993; Martarano et al., 1994; Meyer et al, 1996) . Extensive genetic heterogeneity in ORF S3 exists between different EIAV isolates (Alexanderson and Carpenter, 1991; Leroux et al., 1997; Belshan et al., 1998 ) that in some cases has been shown to affect the nuclear export activity of the rev protein (Belshan et al., 1998; ). An analysis of sequences deposited in GenBank suggests that there is extensive conservation of W 103 in ORF S3 in the case of EIAV samples isolated directly from infected horses or ponies. However, for example, when EIAV MA-1 was subjected to extensive growth in equine dermal cells substitution of the W 103 residue was observed in six of the seven samples examined. In five of these samples the replacement residue was glutamine, while the sixth resembled EIAV UK in having arginine located at position 103 in ORF S (Belshan et al., 1998) . These results suggest that for optimal replication in E. caballus, EIAV must possess a nonpolar tryptophan residue at position 103 in the second exon of rev, whereas for growth in fibroblastic cell types this requirement switches to a polar glutamine or positively charged arginine. The data presented in this report strongly support this conclusion.
In summary, EIAV UK differs from the 3Ј EIAV PV consensus sequence by the possession of a 68-bp duplication in the LTR and R 103 instead of W 103 in ORF S3. These differences were suboptimal in vivo, being subjected to intense selective pressure resulting in restoration of sequences homologous to the EIAV PV consensus at both locations. Furthermore, removal of the duplication and replacement of R 103 with W 103 produced a modified infectious molecular clone (EIAV UK3 ) with an equivalent (P ϭ 0.03) pathogenic potential to EIAV PV . The results of this study demonstrate that ORF S3 and/or regions of the LTR not previously associated with cis-acting transcriptional control elements can modulate EIAV virulence. Therefore, defined modifications in these genetic elements can be used to determine viral replication levels and hence the pathogenicity in E. caballus.
Materials and methods
PCR amplification and molecular cloning of 4.9-kbp 5Ј terminal fragments from the EIAV PV strain
The 4.9-kbp 5Ј terminal fragment of the EIAV PV strain was amplified from 0.1 g of FEK-infected cell DNA (Cook et al., 1998) using the oligonucleotide primers HindIII/EIAV 1 and EIAV 4861 (Table 1) in conjunction with the Expand High Fidelity PCR System (Roche Molecular Biochemicals, Indianapolis, IN). The reactions (50 l) were prepared as recommended by the manufacturer with 1.5 M MgCl 2 and subjected to 30 cycles of melting at 94°C for 15 s, annealing at 66°C for 30 s, with an extension at 68°C for 8 min. Primer EIAV 4861 encompassed the NcoI restriction endonuclease site at position 4873 in EIAV PV (Fig. 1) .
Therefore, following digestion with HindIII plus NcoI and purification from an agarose gel using Agar ACE (Promega, Madison, WI) as described in the manufacturer's recommendations, the resultant 4.9-kbp fragments were ligated into HindIII-NcoI-digested pLG338/30 plasmid DNA. This plasmid is a low copy number vector that has been shown (Cunningham et al., 1993) to stabilize EIAV gene sequences during molecular cloning in Escherichia coli. Finally the ligated products were used to transform E. coli SURE cells (Stratagene, La Jolla, CA) and the resultant molecular clones designated EIAV PV4.9 .
Construction of EIAV UK2 and EIAV UK3 infectious molecular clones
In EIAV UK2 the majority of its gag-pol sequences were derived from EIAV PV , while the 3Ј 3.3-kbp fragment remained identical to that in EIAV UK . This was accomplished (Fig. 1) by substitution of an AspI (located at nucleotide position 643 in EIAV UK )/NcoI (located at nucleotide position 4873 in EIAV UK ) fragment from EIAV PV4.9 No. 7 into EIAV UK .
EIAV UK3 differed from EIAV UK by the absence of the 68-bp duplication in the 3Ј LTR and by the possession of tryptophan instead of arginine at amino acid position 103 in ORF S3. It was produced by exchanging a BstX1 (located at nucleotide position 7444 in EIAV UK )/EcoRI fragment in EIAV UK with an equivalent region of the genome obtained from a molecular clone that in this particular area possessed complete homology with the EIAV PV consensus sequence (Leroux et al., 1997 ).
In the above substitutions restriction endonuclease digests were conducted according to the manufacturer's recommendations (Roche Molecular Biochemicals) and all fragments were purified by agarose gel electrophoresis followed by extraction with Agar ACE (Promega).
Preparation and infection of equine monocyte-derived macrophage cultures
Equine MDM cultures were prepared from EIAV-seronegative donors as described previously (Maury, 1994; Raabe et al., 1998) except that aphidicolin (Sigma-Aldrich, St. Louis, MO) at 0.5 g/ml was added to the maintenance medium to inhibit the growth of the prefibroblastic cells that are frequently encountered in venous blood samples from horses. The MDMs were seeded into 48-well tissue culture plates at 4 ϫ 10 5 cells per well and incubated at 37°C in 6% CO 2 before being infected with viruses from EIAV UK or EIAV UK3 (8 wells per virus strain) at a m.o.i. of 0.1 TCID 50 . Viral RNA isolated using the High Pure TM Viral RNA kit from 0.2 ml of MDM culture fluids at 6 dpi was quantitated by real-time RT-PCR.
Transfection of cell cultures with infectious molecular clones of EIAV
Plasmid DNA preparations of EIAV UK2 and EIAV UK3 were purified using a Midiprep kit (Qiagen Inc., Santa Clara, CA). These purified preparations (4 g) were transfected into FEK cell cultures (at 2 ϫ 10 5 cells per 35-mm diameter well) by using a polycationic lipid transfection reagent (Lipofectamine; Gibco Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. After a 21-to 24-day incubation period (which included passage and amplification of the cell numbers), tissue culture fluids from transfected cell cultures were screened for released reverse transcriptase activity (Cook et al., 1992) , aliquoted, and stored at Ϫ70°C until further use. The titers of the chimeric virus stocks were determined by performing serial log 10 dilutions in modified Eagle's medium containing 3% fetal bovine serum, 25 mM HEPES, 10 mM NaHCO 3 , 100 IU of penicillin/ml, and 100 g of streptomycin/ml and inoculating each dilution onto fresh FEK cell cultures. These FEK cell cultures were monitored for 21 days, after which the culture fluids were assayed for reverse transcriptase activity (Cook et al., 1992) and the titration endpoint was determined by the Karber method (Dougherty, 1964) .
LTR CAT reporter gene assay
Complete copies of the 3Ј EIAV UK and EIAV UK3 LTRs were generated by PCR using the HindIII EIAV 1 -XbaI EIAV 8283 oligonucleotide primer pair (Table 1) on DNA templates consisting of 3Ј 3.3-kbp (NcoI/EcoRI) molecularly cloned fragments of the relevant proviral genomes. Reactions were conducted using the Expand High Fidelity PCR System (Roche), with 30 cycles of melting at 94°C for 20 s, annealing at 66°C for 30 s, and extension at 68°C for 60 s. The HindIII and XbaI sites in the oligonucleotide primers enabled directional ligation of the resultant PCR fragments into the pCAT-Basic plasmid vector (Promega). Ligation products were used to transform E. coli SCS110 (dam) cells (Stratagene) and four of each resultant EIAV UK and EIAV UK3 LTR clone (pUKLTR-CAT, pUK3LTR-CAT) were subjected to nucleotide sequence analysis to ensure that mutations had not been introduced into the LTR during the amplification or molecular cloning procedures. The pUKLTR-CAT and pUK3LTR-CAT constructs (3 g) were transfected in triplicate as described above into ED (obtained from the American Type Culture Collection-ATCC CCL-57) cell cultures in conjunction with 1 g of the EIAV tat protein expression vector pRS-ETAT-M (kindly donated by Dr. David Derse, National Cancer Institute, Frederick, MA) or 1 g of pCI (Promega) control vector. Transfected ED cells were incubated for 40 h at 37°C in 5% CO 2 prior to analysis of CAT expression using a CAT ELISA kit (Roche) on 250 g of cell lysate.
Detection of the 68-bp duplication in viral RNA from plasma samples isolated from EIAV UK -infected animals
Plasma samples (2 ml) harvested at various times following infection with EIAV UK were centrifuged at 37,100 g for 2 h at 4°C. The resultant pellets were resuspended in 200 l of diethyl pyrocarbonate (DEPC)-treated H 2 O and RNA extracted using the High Pure Viral RNA kit (Roche Molecular Biochemicals) as directed by the manufacturer. After elution from the High Pure matrix material the nucleic acids were ethanol precipitated in the presence of 3.75 M ammonium acetate. Precipitated nucleic acids were washed once in 70% ethanol, allowed to air dry, and resuspended in 5 l of DEPC-treated H 2 O containing 4 units of RNasin (Promega). These RNA samples were subjected to analysis by RT-PCR using a pair of oligonucleotide primers which spanned the U3 region of the LTR. The 5Ј primer (EIAV 7812 , Table 1 ) was located within the coding sequences for the transmembrane glycoprotein at nucleotide position 7812 in the EIAV UK molecular clone (Cook et al., 1998) , while the 3Ј primer (EIAV 8179 , Table 1 ) was located within the R region of the LTR at position 8179. With an EIAV UK viral preparation these primers would be predicted to produce a 398-bp product, whereas viruses containing an LTR of normal size would give rise to a 330-bp fragment. Reverse transcription reactions were performed using 2.0 l of RNA sample in 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 4.5 mM MgCl 2 , 1 mM each dNTP, 1 unit/l of RNase inhibitor, 20 pmol of the EIAV 8179 primer, and 2.5 units/l of Moloney murine leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA). Each reaction was adjusted to a final volume of 20 l, overlaid with mineral oil, and incubated at 42°C for 45 min before being heated to 99°C for 5 min. Following reverse transcription, the concentration of the reaction mixture was adjusted to 2 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 20 pmol of the EIAV 7812 primer, and 2.5 units of AmpliTaq DNA polymerase (Applied Biosystems) in a final volume of 100 l. These reaction mixtures were subjected to 5 cycles of melting at 95°C for 20 s, annealing at 54°C for 30 s, and extension at 72°C for 60 s. This was followed by 30 cycles of melting at 95°C for 20 s, annealing at 50°C for 30 s, and extension at 72°C for 60 s. The products of these reactions were analyzed by electrophoresis in 1.2% agarose gels and visualized by ethidium bromide staining.
Molecular cloning of RT-PCR products derived using the EIAV 7812/8179 oligonucleotide primer pair
Following RT-PCR using the EIAV 7812/8179 oligonucleotide primer pair products detected at 8 and 12 dpi from four of the EIAV UK -infected animals described above were isolated from 1.2% low-melting-point agarose gels by digestion with AgarAce (Promega) according to the manufacturer's recommendations. Following purification each fragment was molecularly cloned into the pT7 Blue-3 vector using the Perfectly Blunt cloning kit (Novagen, Inc., Madison, WI). Five molecular clones were selected of each fragment at both time points from all four animals. Plasmid DNA was prepared from each molecular clone using a Qiagen Miniprep (Qiagen) and the nucleotide sequence determined in both directions using the oligonucleotide primers EIAV 7812 and EIAV 8179 .
Identification of the amino acid residue at position 103 in ORF S3 in EIAV UK -infected animals
Viral RNA was prepared from plasma samples collected at various times postinfection with EIAV UK as outlined above. This viral RNA was subjected to reverse transcription using the EIAV 8179 oligonucleotide primer as described for the analysis of the 68-bp duplication. The resultant cDNA was amplified by PCR, again as outlined above for the analysis of the 68-bp duplication, except that 20 pmol of the EIAV 7034 oligonucleotide primer (Table 1 ) was added to the reaction mixture. These reaction mixtures were subjected to 5 cycles of melting at 95°C for 20 s, annealing at 56°C for 30 s, and extension at 72°C for 2 min. This was followed by 30 cycles of melting at 95°C for 20 s, annealing at 51°C for 30 s, and extension at 72°C for 2 min. The resultant PCR products were isolated from 1.2% low-melting-point agarose gels by digestion with AgarAce and molecularly cloned into the pT7 Blue-3 vector using the Perfectly Blunt cloning kit. These molecular clones were sequenced using overlapping EIAV primers (Leroux et al., 1997) .
Nucleotide sequencing
Plasmid DNA was extracted and purified with Miniprep or Midiprep kits (Qiagen). This purified DNA was sequenced using a Thermo Sequenase Cy 5.5 dye terminator cycle sequencing kit (Amersham Pharmacia Biotech, Piscataway, NJ) using overlapping EIAV primers derived from published sequences (Cook et al., 1998; Leroux et al., 1997; Stephens et al., 1986) . The sequences were resolved using an OpenGene automated DNA sequencing system (Visible Genetics Inc., Toronto, Ontario, Canada).
Experimental subjects
The ponies (662, 839, 873, and 930) were of mixed breed origin, while the majority of the horses (1, 6, 9, 10, 985, and 986) were Thoroughbreds. The ages of these animals ranged from 2 to Ն20 years. Before inclusion in an experiment the animals were tested and found negative for antibodies against EIAV using tests approved by the United States Department of Agriculture. The animals were housed in screened box stalls to exclude hematophagous insects and all handling protocols pertaining to them received prior approval from the University of Kentucky Institutional Animal Care and Use Committee. The horses and ponies were treated with Ivermectin for internal parasites and vaccinated against tetanus toxoid (Merck, Sharp & Dohme, Rahway, NJ). Animals were inoculated intravenously, using clarified (3000 g for 30 min at 4°C) cell culture fluids from EIAV UK -, EIAV UK1 -, EIAV UK2 -, EIAV UK3 -, or EIAV UK4 -transfected cell cultures at 4 ϫ 10 6 50% tissue culture infective doses (TCID 50 ). All animals were monitored on a daily basis for rectal temperature and overall clinical status. Blood samples were collected at regular intervals by jugular venipuncture into sterile glass evacuated tubes (BectonDickinson, Rutherford, NJ) for serum or with EDTA for plasma (Sherwood Medical, St. Louis, MO). Serum and plasma were stored at Ϫ20 and Ϫ70°C, respectively. In addition, fresh blood samples collected in the presence of EDTA were analyzed to determine platelet numbers using the Idexx QBC VetAutoread hematology system (Idexx Laboratories, Inc., Westbook, ME). Platelet numbers were determined at least weekly and during each febrile episode (Ն39.0°C). Virus isolation from plasma samples on FEK cell cultures was as described previously Wang et al., 1994) and determination of viral titers in these samples was conducted by inoculation of serial log 10 dilutions onto FEK cells. All cultures were maintained for at least 21 days, after which they were assayed for reverse transcriptase activity (Cook et al., 1992 ). Serum samples were tested for antibodies against EIAV using tests approved by the United States Department of Agriculture, including agar gel immunodiffusion (EIA-AGID, Idexx Laboratories, Inc.) and enzyme-linked immunosorbent assay systems (EIA-CELISA, Idexx Laboratories Inc., VI-RACHEK/EIA, Synbiotics Corp., San Diego, CA, SA-ELISAII, Viral Antigens, Inc., Memphis, TN).
Real-time RT-PCR quantitation of EIAV RNA from plasma samples
A single-tube RT-PCR using a fluorogenic real-time PCR detection method for the quantitation of EIAV gag gene containing RNA has been described previously (Cook et al., 2002) . To compensate for variations inherent in sample preparation this utilizes a multiplex procedure in which plasma samples are seeded with 10 8 copies of a green fluorescent protein (gfp) RNA transcript (Klein et al., 2001 ). The use of separate gfp-specific primers and a fluorogenic probe permits the simultaneous calculation of nucleic acid recovery rate along with the copy number of EIAV RNA molecules (Cook et al., 2002) .
Each 25-l RT-PCR mixture contained 1 ϫ EZ buffer (Applied Biosystems, Foster City, CA, 50 mM bicine, 115 mM potassium acetate, 8% wt/vol glycerol, pH 8.2), 300 M each dNTP, 2.5 mM manganese acetate, 200 nM EIAV 1572F, 200 nM EIAV 1769R, 125 nM EIAV probe, 40 nM GFP F, 40 nM GFPR, 125 nM GFP probe, 40 units of RNasin, and 2.5 units of rTth (Applied Biosystems). Reverse transcription and amplification were performed using the Smart Cycler real time thermal cycler (Cepheid, Sunnyvale, CA). To prevent binding of nuclei acids and polymerases to the reaction tubes, Cepheid recommends the addition of an "Additive Reagent." Therefore, this reagent was added to each reaction, giving a final concentration of 0.2 mg/ml of bovine serum albumin (nonacetylated), 0.15 M trehalose, and 0.2% Tween 20.
The analysis of data was performed with version 1.2b Smart Cycler Software using the preset default values of the Primary Curve Analysis. Standard curves were produced by preparing log 10 dilutions of an in vitro synthesized (Cook et al., 2002) EIAV gag gene RNA transcript (with each dilution seeded with 10 8 molecules of gfp transcript) and analyzed by plotting the cycle number versus the fluorescent signal. A sample was deemed positive once the fluorescence signal exceeded the preset default value of 30 fluorescent units. The cycle number at which this occurred was defined as the cycle threshold.
